Curtis J. Henrich, Ph.D.

Principal Scientist, Leidos Biomedical Research, Inc.
Molecular Targets Program
Head, Assay Development and Screening Section

Team Member of:

Dr. Henrich coordinates bioassay development, high-throughput screening, and application of assays to natural products isolation within the Molecular Targets Program.

Areas of Expertise
1) bioassay development, 2) high-throughput screening, 3) natural products isolation

Contact Info

Curtis J. Henrich, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 538, Room 167
Frederick, MD 21702-1201
Ph: 301-846-6054
henrichcj@mail.nih.gov
Permalink

Coordination of bioassay development, high-throughput screening, and application of assays to natural products isolation.

Selected Publications

  1. Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor.
    Bajer MM, Kunze MM, Blees JS, Bokesch HR, Chen H, Brauß TF, Dong Z, Gustafson KR, Biondi RM, Henrich CJ, McMahon JB, Colburn NH, Schmid T, Brüne B.
    Biochem. Pharmacol.. 88: 313-21, 2014. [ Journal Article ]
  2. Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.
    Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.
    Phytochem Lett. 7: 42-45, 2014. [ Journal Article ]
  3. High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells.
    Henrich CJ, Budhu A, Yu Z, Evans JR, Goncharova EI, Ransom TT, Wang XW, McMahon JB.
    Chem Biol Drug Des. 82: 131-9, 2013. [ Journal Article ]
  4. Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth.
    Devkota KP, Wilson J, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.
    J. Nat. Prod.. 76: 59-63, 2013. [ Journal Article ]
  5. Matching the power of high throughput screening to the chemical diversity of natural products.
    Henrich CJ, Beutler JA.
    Nat Prod Rep. 30: 1284-98, 2013. [ Journal Article ]

Dr. Henrich received his Ph.D. in biochemistry from the University of Michigan (thesis research on erythrocyte senescence-related glycoconjugates). He conducted his postdoctoral research in Michigan and at the University of California, San Francisco, which was followed by 14 years in the biotechnology industry (Life Technologies, Inc. and a now defunct start-up called Aptus Pharmaceuticals). He joined the Molecular Targets Program (formerly, Molecular Targets Laboratory) in 2003 first as a Consultant, then as a Senior Scientist affiliated with Leidos Biomedical Research, Inc. (formerly, SAIC-Frederick, Inc.)

Name Position
Emad Darvishi Ph.D. Postdoctoral Fellow (Visiting)
Ancy Nalli Ph.D. Postdoctoral Fellow (Visiting)
Emily Smith M.S. Research Associate (Leidos)
Antony Wamiru Senior Research Technician (Leidos)
Jennifer A. Wilson Biological Lab Technician
Girma M. Woldemichael, Ph.D. Scientist II (Leidos)